Soligenix shares are trading higher after the company announced clinical results from a comparative study evaluating HyBryte against Valchlor in the treatment of cutaneous T-cell lymphoma.
Portfolio Pulse from Benzinga Newsdesk
Soligenix shares are trading higher following the announcement of positive clinical results from a comparative study evaluating HyBryte against Valchlor for treating cutaneous T-cell lymphoma.
June 25, 2024 | 11:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Soligenix shares are experiencing an upward trend after the company reported favorable clinical results from a study comparing HyBryte to Valchlor for cutaneous T-cell lymphoma treatment.
The positive clinical results for HyBryte in comparison to Valchlor are likely to boost investor confidence in Soligenix's product pipeline, leading to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100